Antibody

#Antibody #Antibody-based therapeutics #Biotechnology #Drug development #Drug discovery #Genomics #Single-cell analysis

Using single-cell technology to create human antibody-based therapeutics

San Francisco-based biotechnology company Infinimmune is emerging from stealth with its $12 million seed financing. The company is co-founded by former team leaders and multi-disciplinary tool builders from 10x Genomics. Taking a human-first approach, Infinimmune is leveraging single-cell technology to create truly human antibody-based therapeutics directly derived from the human… Read More

#Business & Investment #Exclusive Content

#Antibodies #Antibody #Antibody discovery workflow #Antibody-based therapeutics #Bethyl Laboratories #Drug discovery

Why choose Bethyl antibodies for your R&D

This article is sponsored by Bethyl Laboratories. For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. We are vertically-integrated from immunisation through manufacturing and validation. All of our antibodies are… Read More

#News

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three… Read More

#Business & Investment #Market Reports #News

Two scientists working in a research laboratory
#Antibody #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Merck #Mersana Therapeutics #Partnership #Tumours

Research partners hope to develop novel antibody-drug conjugates

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets.  Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary… Read More

#Business & Investment #News

Myeloma cells
#Antibody #Cancer research #Europe #European Medicines Agency #Janssen #Marketing approval authorisation #Myeloma #T-Cells

Janssen seeks European approval for multiple myeloma drug

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).   Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal… Read More

#Cancer Research #News

Patient with type 1 diabetes
#Antibody #Diabetes #FDA #Type 1 diabetes #US

FDA approves first disease-modifying therapy for T1D

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for anti-CD3-directed antibody TZIELD (teplizumab-mzwv), the first immunomodulatory treatment for type 1 diabetes (T1D).   It is approved for intravenous use to delay the onset of stage 3 T1D in adult and paediatric patients aged eight years… Read More

#News #Regulatory

Antibodies
#Antibody #Antibody-based therapeutics #eBook #Monoclonal antibodies #Stability characterisation

New eBook: Efficiently develop antibody-based therapeutics 

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing.  Antibodies are affected by many factors along their journey to become therapeutics. Read More

#News

Jigsaw puzzle of the brain
#Alzheimer's #Antibody #Clinical trial #Cognitive impairment #Drug development #Drug discovery #Phase III trial

New Alzheimer’s treatment reduces decline in Phase III trial

A new Alzheimer’s disease (AD) treatment has been shown to reduce clinical decline in mild cognitive impairment (MCI) due to AD and mild AD with confirmed presence of amyloid pathology in the brain.  Eisai and Biogen’s anti-amyloid beta (Aβ) protofibril antibody lecanemab met the primary endpoint and… Read More

#News

Antibodies
#Afucosylated mAb expression #Antibody #Antibody-dependent cellular cytotoxicity #Glycoengineered antibodies #Monoclonal antibodies

New App Note: Afucosylated mAb expression and antibody efficacy

Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in… Read More

#News

#Afucosylated mAb expression #Antibody #Antibody-dependent cellular cytotoxicity #Glycoengineered antibodies

Afucosylated mAb expression benefits therapeutic antibody efficacy

Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in… Read More

#App Notes #Intelligence #Resources

#Antibody #Drug discovery #Monoclonal antibodies #Webinar

Webinar – applications in early monoclonal antibody discovery

In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. The webinar elaborates on the use of the Octet BLI for quality control of proteins,… Read More

#News

#Antibody #Autoimmune disease

Immutep granted Japanese patent for immunosuppressive antibody  

Biotechnology company Immutep has been a granted a patent for its immunosuppressive antibody by the Japanese Patent Office.  Immutep’s IMP761 is an immunosuppressive agonist antibody to LAG-3 – a cell surface molecule which plays a role in regulating T cell function, and which has been identified as… Read More

#News

Antibodies
#Antibody #Pharmaceutical

Absolute Antibody expands humanised services  

Absolute Antibody has expanded it Prometheus antibody humanisation service to deliver humanised antibodies from a wider range of species than it had previously had.   The company’s Prometheus antibody humanisation service now offers humanisation from -murine origin species, including rabbit antibodies and single-domain camelid nanobodies.  Humanisation… Read More

#News

#Antibody #Antibody reagents #Assays

Exclusive DDW event: generate and validate critical antibody reagents

Antibodies are critical reagents applied in multiple biological areas, such as scientific research, therapeutics, and diagnosis. High-quality and reliable antibody reagents are the foundation of good assay performance. To learn more generating and validating critical antibody reagents join this free event hosted by DDW and supported by Sino Biological. It… Read More

#News

#Antibody #Biologics #Biosciences #Drug discovery

Twist Bioscience acquires Abveris to bolster biopharma capabilities  

Twist Bioscience has acquired Abveris, which will offer Twist comprehensive antibody discovery and characterisation services using its DiversimAb family of hyperimmune mouse models, the output of which can be humanised using the Twist antibody optimisation solution to develop biologics for rapid clinical advancement.   Emily Leproust, CEO and co-founder of Twist Bioscience, believes that the addition of the Abveris discovery… Read More

#News